📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-27 19:28
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
CARE Upgrades Hester Biosciences' Long-Term Bank Facilities Rating to 'BBB+; Stable' from 'BBB'
CARE Ratings has upgraded Hester Biosciences' credit ratings across bank facilities totaling ₹113.67 crore. Long-term facilities of ₹48.45 crore (reduced from ₹66.25 crore) were upgraded to CARE BBB+; Stable from CARE BBB; Stable. Long-term / short-term facilities (₹65.00 crore) and short-term facilities (₹0.22 crore) were upgraded to CARE BBB+ / CARE A2 and CARE A2, respectively, driven by operational and financial performance in FY26 and Q1FY27.
Confidence: HIGH
What changedCARE Ratings upgraded Hester Biosciences' long-term bank facilities rating to 'CARE BBB+; Stable' from 'CARE BBB; Stable' and short-term rating to 'CARE A2' from 'CARE A3+'.
Why it mattersThe rating upgrade signals an improving financial and liquidity profile post-FY26 earnings recovery, potentially lowering future interest costs and improving debt terms.
Total rated bank facilities: ₹113.67 croreRated facilities vs TTM revenue: ~34.9%Long-term facilities rated: ₹48.45 croreCash credit limit: ₹60.00 croreOutstanding foreign currency loan: $4.00 Mn (₹37.87 crore)
📅 Short termPositive sentiment driver reflecting strengthening creditworthiness and sound balance sheet position.
📈 Long termImproves financial flexibility and lowers risk premium for prospective debt-funded expansions or working capital scale-up.
⚠ Risk flags
- Forex exposure risk on outstanding $4.00 million SBI term loan
- Dependency on lumpy institutional tender business in export and regional markets
Key Highlights
Long-term bank facility rating upgraded to CARE BBB+; Stable from CARE BBB; Stable across ₹48.45 crore.
Short-term facility rating upgraded to CARE A2 from CARE A3+ across fund and non-fund based limits.
Total bank facilities under rating stand at ₹113.67 crore, representing ~34.9% of FY26 TTM revenue.
Outstanding long-term debt as on June 30, 2026 includes ₹10.58 crore in INR term loans and ₹37.87 crore ($4.00 million) in foreign currency term loans.
👀 What to Watch
Track whether the rating upgrade translates into lower borrowing costs on working capital lines and monitor operating cash flow trends in upcoming quarterly results.
88% Standalone PAT Growth in Q1 FY27; Gates Foundation Waives $7M Debt for Africa
Hester Biosciences reported a strong standalone performance for Q1 FY27 with 14% revenue growth and an 88% surge in PAT, driven by a 48% growth in the Poultry Healthcare division. Gross margins expanded significantly from 69% to 78% due to a favorable product mix and operational efficiencies. A major highlight is the restructuring of the Gates Foundation loan for Hester Africa, reducing the debt from $12 million to $5 million and making it interest-free. Despite standalone strength, consolidated revenue declined 8% due to lumpy institutional orders in Nepal and Africa.
Confidence: HIGH
What changedHester has successfully improved its standalone margin profile through a better product mix and secured a significant debt waiver that de-risks its international balance sheet.
Why it mattersThe 900 bps margin expansion and debt reduction significantly improve the company's cash flow outlook and reduce the drag from the African subsidiary on consolidated earnings.
Standalone PAT Growth (YoY): 88%Gross Margin: 78%Debt Reduction (Africa): $7 millionIndia Plant Capex: ₹182 CrCapex vs Net Worth: 47.1%Poultry Division Growth: 48%
📅 Short termThe market is likely to react positively to the sharp margin expansion and the one-time exceptional gain from the debt waiver.
📈 Long termThe shift from tender-based business to private commercial markets and the expansion of the biological pipeline are structural positives for long-term valuation.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Lumpy revenue from government tenders in the Animal Healthcare division
- Geopolitical and operating challenges in African markets
Key Highlights
Standalone PAT increased by 88% YoY, while EBITDA grew by 95% reflecting strong operating leverage.
Gross margins improved to 78% from 69% in the previous year's corresponding quarter.
Poultry Healthcare division recorded 48% growth, supported by new health products and deeper market penetration.
Gates Foundation reduced Hester Africa's outstanding loan by $7 million (from $12M to $5M) and waived accrued interest.
Ongoing ₹182 Cr investment in the India plant is on track to be operational by March 2026.
👀 What to Watch
Watch for the operationalization of the ₹182 Cr India plant expansion by March 2026 and the progress toward the FY28 breakeven target for African operations.
Q1 FY27: Standalone PAT up 88% to ₹14.7 Cr; ₹85.3 Cr Exceptional Gain from Debt Reduction
Hester Biosciences reported a strong standalone performance for Q1 FY27 with revenue growing 14% to ₹72.66 Cr and PAT rising 88% to ₹14.71 Cr. The Poultry Healthcare division was the primary driver, growing 48% YoY, while the Animal Healthcare division saw a 50% decline due to government tender delays. A massive consolidated PAT surge of 459% was recorded, primarily due to an ₹85.35 Cr exceptional gain following a debt reduction agreement with the Gates Foundation for Hester Africa. Standalone EBITDA margins expanded significantly to 36% from 21% in the previous year.
Confidence: HIGH
What changedHester achieved a significant operational turnaround in its standalone poultry business and secured a major debt haircut for its African subsidiary, substantially de-risking its consolidated balance sheet.
Why it mattersThe debt reduction at Hester Africa removes a significant financial overhang, while the 48% growth in poultry vaccines demonstrates successful market penetration in the private commercial segment, reducing reliance on volatile government tenders.
Standalone Revenue (Q1): ₹72.66 CrStandalone PAT (Q1): ₹14.71 CrExceptional Gain (Consolidated): ₹85.35 CrExceptional Gain vs TTM Revenue: 26.18%Poultry Healthcare Growth: 48%Standalone EBITDA Margin: 36%
📅 Short termThe stock is likely to react positively to the strong standalone margin expansion and the massive bottom-line boost from the debt restructuring, despite the weakness in the animal healthcare segment.
📈 Long termThe structural shift toward a higher-margin private product mix and the de-leveraging of the African unit position the company for more stable earnings growth over the next 2-3 years.
⚠ Risk flags
- High volatility in Animal Healthcare revenue due to 50% dependency on government tender timing
- Continued variability in institutional orders from Nepal and Africa operations
Key Highlights
Standalone Revenue increased 14% YoY to ₹72.66 Cr, led by a 48% surge in Poultry Healthcare sales.
Consolidated PAT reached ₹96.73 Cr, boosted by an ₹85.35 Cr exceptional gain from restructuring a $12 million loan to $5 million.
Standalone Gross Profit margins improved to 78% from 69% due to a favorable product mix and operational efficiencies.
Animal Healthcare division revenue fell 50% to ₹10.84 Cr, attributed to the timing of government-led immunization programs.
Hester Africa's outstanding loan from the Gates Foundation was reduced by $7 million and made interest-free.
👀 What to Watch
Investors should monitor the recovery of the Animal Healthcare tender business in upcoming quarters and the progress of the ₹182 Cr India plant expansion. The sustainability of the 78% gross margin in the absence of lumpy government contracts is a key metric to watch.
₹85.35 Cr Exceptional Gain Drives Hester Bio Q1 PAT to ₹96.73 Cr; Debt Reduced by $7M
Hester Biosciences reported a consolidated PAT of ₹96.73 cr for Q1 FY27, a significant jump from ₹17.30 cr YoY, primarily due to an ₹85.35 cr exceptional gain. This gain resulted from a loan restructuring with the Gates Foundation, which reduced the principal from $12 million to $5 million and waived all interest. While consolidated revenue from operations declined 8.2% YoY to ₹77.24 cr, the Poultry Healthcare segment showed robust growth of 47.5% YoY. However, the Animal Healthcare segment saw a sharp 64% decline in revenue, impacting overall top-line performance.
Confidence: HIGH
What changedThe company successfully restructured its debt with the Gates Foundation, leading to a $7 million principal reduction and interest waiver, while the business mix shifted heavily toward Poultry Healthcare.
Why it mattersThe debt reduction significantly strengthens the balance sheet and reduces future interest costs. However, the volatility in the Animal Healthcare segment highlights the company's ongoing challenge with lumpy institutional and tender-based orders.
Exceptional Gain: ₹85.35 crConsolidated Revenue (Q1): ₹77.24 crPoultry Segment Revenue: ₹62.13 crAnimal Segment Revenue: ₹15.11 crLoan Principal Reduction: $7 millionExceptional Gain vs TTM PAT: ~150%
📅 Short termThe stock may react positively to the massive headline profit and the substantial debt reduction, which improves the net worth significantly.
📈 Long termThe balance sheet cleanup is a structural positive, but long-term value depends on stabilizing the Animal Healthcare segment and successfully scaling the Africa operations to breakeven.
⚠ Risk flags
- High volatility in Animal Healthcare segment revenue
- Dependency on institutional/tender-based orders
- Segment loss in Animal Healthcare (₹4.18 cr loss at consolidated level)
Key Highlights
Exceptional gain of ₹85.35 cr recognized following a loan waiver and restructuring with the Gates Foundation (USA).
Consolidated revenue from operations stood at ₹77.24 cr, down 8.2% from ₹84.11 cr in Q1 FY26.
Poultry Healthcare segment revenue grew 47.5% YoY to ₹62.13 cr, up from ₹42.12 cr.
Animal Healthcare segment revenue plummeted 64% YoY to ₹15.11 cr from ₹41.98 cr.
Consolidated EPS for the quarter reached ₹113.71, compared to ₹20.33 in the same quarter last year.
👀 What to Watch
Investors should focus on the sustainability of the Poultry segment's growth and the reasons behind the sharp decline in Animal Healthcare. Watch for the operationalization of the BSL-3 and Fill-Finish facilities, which are currently listed as unallocated assets.
Hester Biosciences Sets July 14 as Record Date for INR 11 Per Share Final Dividend
Hester Biosciences Limited has fixed July 14, 2026, as the record date to determine shareholder eligibility for a final dividend of INR 11 per equity share for the financial year. This dividend represents a 110% payout on the face value of INR 10 per share. The distribution is subject to shareholder approval at the company's 39th Annual General Meeting. The record date also serves as the cutoff for determining members entitled to participate in e-voting for the AGM.
Key Highlights
Record date for dividend and AGM e-voting fixed for July 14, 2026.
Proposed final dividend of INR 11 per equity share (110% of face value).
Face value of the company's equity shares is INR 10 each.
Dividend payout is subject to approval at the 39th Annual General Meeting and applicable tax deductions.
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date, which typically precedes the July 14 record date. Monitor the 39th AGM outcomes for final dividend declaration and payment timelines.
Hester Biosciences FY26 Consolidated PAT Surges 99% to ₹574.8M; AGM Set for July 21
Hester Biosciences reported a robust financial performance for FY 2025-26, with consolidated profit after tax (PAT) jumping 99% to ₹574.84 million despite a modest 7% revenue growth to ₹3,325.99 million. The company achieved significant margin expansion, with standalone EBITDA rising 56% to ₹871.03 million, driven by a favorable product mix and cost discipline. Key operational milestones include the commercialization of the H9N2 Avian Influenza vaccine and the repurposing of the BSL-3 facility for veterinary use. The company has scheduled its 39th AGM for July 21, 2026, and confirmed a dividend payout ratio of 18%.
Key Highlights
Consolidated PAT grew by 99% YoY to ₹574.84 million, while Standalone PAT rose 64% to ₹521 million.
Poultry Healthcare division recorded a strong 24% growth, supported by the launch of the H9N2 Avian Influenza vaccine.
Standalone EBITDA increased by 56% to ₹871.03 million, reflecting improved operational efficiencies.
The company capitalized its Fill-Finish and BSL-3 facilities, enhancing manufacturing scale-up capabilities.
Final dividend payment is scheduled on or after July 28, 2026, for shareholders as of the July 14 cut-off date.
👀 What to Watch
Investors should note the significant improvement in profitability and margins, suggesting successful cost management and a shift toward higher-margin products. The stock warrants a positive outlook given the successful commercialization of new vaccines and the operational readiness of advanced BSL-3 facilities.
Hester Bio Subsidiary Debt Reduced by USD 7M; Gates Foundation Waives Interest
Hester Biosciences Africa, a wholly-owned subsidiary of Hester India, has successfully renegotiated its loan terms with the Gates Foundation. The outstanding loan facility has been significantly reduced from USD 12 million to USD 5 million, representing a USD 7 million reduction. Furthermore, the lender has waived all accrued interest and converted the remaining balance into a zero-interest loan. These changes, including an extended repayment tenor, will substantially improve the subsidiary's liquidity and reduce the financial pressure on the parent company's corporate guarantee.
Key Highlights
Outstanding loan amount reduced by USD 7 million, from USD 12 million to USD 5 million
Complete waiver of accrued interest amounts by the Gates Foundation
Future interest rate set to 0% on the remaining USD 5 million loan balance
Revision of repayment schedule and extension of loan tenor to improve cash flow
Corporate guarantee by Hester India continues for the reduced loan amount
👀 What to Watch
Investors should view this as a significant positive development that de-leverages the consolidated balance sheet and improves the path to profitability for the African operations. Monitor the subsidiary's operational performance to see if these savings are reinvested into growth.
Hester Biosciences Q4 FY26 PAT Surges 174% Driven by Poultry Segment and Exceptional Gains
Hester Biosciences reported a strong performance for Q4 FY26, with standalone revenue growing 22% and PAT jumping 174% YoY. The Poultry Healthcare division was the primary growth engine, recording 41% growth in Q4, while the consolidated annual PAT doubled, partly aided by exceptional income from a stake sale in Texas Lifesciences. The company has successfully capitalized its new Fill-Finish and BSL-3 facilities and received licenses for the H9N2 Avian Influenza vaccine. Despite earlier delays in government tenders, the company executed the supply of 6.3 crore PPR vaccine doses in the final quarter.
Key Highlights
Standalone Q4 PAT increased by 174% YoY, while consolidated FY26 PAT grew by 100% to reach record levels.
Poultry Healthcare division revenue grew 41% in Q4 and 21% for the full financial year FY26.
Supplied 6.3 crore doses of PPR vaccine in Q4 FY26, signaling a recovery in the Animal Healthcare tender business.
Received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine, targeting the private commercial market.
Capitalized new Fill-Finish and BSL-3 facilities to enhance drug product capacity and operational efficiency.
👀 What to Watch
Investors should focus on the company's transition toward higher-margin biologicals and the scaling of the H9N2 vaccine. The successful capacity expansion and recovery in tender execution provide a positive outlook for FY27.
Hester Biosciences FY26 Consolidated Revenue Hits ₹332.6 Cr; PAT Surges to ₹57.5 Cr
Hester Biosciences reported a strong financial performance for FY 2025-26, with consolidated revenue reaching ₹332.60 crore. The company witnessed a significant recovery in profitability, with consolidated Profit After Tax (PAT) jumping to ₹57.48 crore from ₹21.17 crore in the previous fiscal year. Hester maintains a dominant 35% market share in the Indian poultry vaccine market and is the world's largest supplier of the PPR vaccine. The company is strategically diversifying, with the Animal Healthcare division now contributing 38% to consolidated revenue.
Key Highlights
Consolidated revenue grew to ₹332.60 crore in FY26 compared to ₹311.10 crore in FY25.
Consolidated PAT surged to ₹57.48 crore, a substantial increase from ₹21.17 crore in the prior year.
Maintains a 35% market share in the Indian poultry vaccine segment as the second-largest manufacturer.
Annual manufacturing capacity stands at 8.6 billion doses in India, 1.24 billion in Nepal, and 1.5 billion in Africa.
Animal Healthcare division's revenue contribution rose to 38% on a consolidated basis, up from 29% on a standalone basis.
👀 What to Watch
Investors should view the sharp turnaround in profitability and margin expansion as a positive sign of operational efficiency. The company's leading position in global vaccine banks and expansion into the Petcare segment provide long-term growth visibility.
Hester Biosciences: Promoters Ravin and Bela Gandhi Seek Reclassification of 9.45% Stake to Public
Hester Biosciences has received formal requests from two members of its promoter group, Mr. Ravin Gandhi and Ms. Bela Gandhi, to be reclassified as public shareholders. Mr. Ravin Gandhi holds a 4.74% stake (403,320 shares) and recently resigned from the Board, while Ms. Bela Gandhi holds a 4.71% stake (400,635 shares). Together, they represent 9.45% of the company's voting rights and have declared they no longer exercise management control or hold special rights. The company is now initiating the necessary regulatory steps under SEBI guidelines to process these requests.
Key Highlights
Mr. Ravin Gandhi (4.74% stake) and Ms. Bela Gandhi (4.71% stake) have applied for reclassification from 'Promoter' to 'Public' category.
The combined shareholding involved in the reclassification request totals 803,955 equity shares or 9.45% of the company.
Mr. Ravin Gandhi resigned from the Board of Directors effective May 12, 2026, to facilitate this transition.
Ms. Bela Gandhi confirmed she has had no involvement in company management for the last 12 years.
The reclassification is subject to approval from the company's shareholders and the stock exchanges under SEBI Regulation 31A.
👀 What to Watch
Investors should view this as a standard regulatory restructuring of shareholding; however, monitor if this leads to any future secondary market sales by these individuals once they are classified as public. The move does not impact the company's day-to-day operations or business fundamentals.
Hester Biosciences Reports FY26 Consolidated Revenue of ₹332.6 Cr; 35% Poultry Vaccine Market Share
Hester Biosciences reported a consolidated revenue of ₹332.60 crore for FY 2025-26, with a consolidated PAT of ₹28.83 crore. The company maintains a dominant position as India's second-largest poultry vaccine manufacturer with a 35% market share. Notably, standalone PAT was significantly higher at ₹52.10 crore, suggesting that international subsidiaries in Nepal and Africa are currently impacting overall group profitability. The company is strategically focusing on the Petcare segment and large-scale vaccine projects in Africa to drive future growth.
Key Highlights
Consolidated revenue reached ₹332.60 Cr in FY26, with Poultry Healthcare contributing 62% and Animal Healthcare 38%.
Standalone PAT stood at ₹52.10 Cr, while consolidated PAT was lower at ₹28.83 Cr due to subsidiary performance.
Maintains a 35% market share in the Indian poultry vaccine market and is the world's largest supplier of the PPR vaccine.
Total annual manufacturing capacity across India, Nepal, and Africa plants exceeds 11.3 billion doses.
Ongoing expansion into the Petcare division and the VITAL 2 project for ruminant vaccines in Kenya, Nigeria, and Tanzania.
👀 What to Watch
Investors should focus on the company's ability to improve the profitability of its African and Nepal subsidiaries to match its strong standalone performance. The dominant market share in poultry vaccines and entry into the high-margin Petcare segment are positive long-term indicators.
Hester Biosciences Q4 PAT Surges 174% to INR 26.38 Cr; Declares INR 11 Dividend
Hester Biosciences reported a robust performance for Q4 FY26, with standalone revenue growing 22% YoY to INR 93.71 crore. Net profit for the quarter saw a significant jump of 174% YoY to INR 26.38 crore, bolstered by an exceptional gain of INR 6.99 crore from a subsidiary sale. The Board has recommended a healthy dividend of INR 11 per share (110% of face value). The Poultry Healthcare segment continues to be the primary growth engine, while the company also confirmed the re-appointment of Ms. Priya Gandhi as Executive Director.
Key Highlights
Standalone Q4 FY26 PAT rose to INR 263.84 million from INR 96.35 million in the previous year's quarter.
Full-year FY26 PAT increased by 63.6% to INR 521.00 million compared to INR 318.42 million in FY25.
Recommended a final dividend of INR 11 per equity share (110%) for the financial year 2025-26.
Poultry Healthcare segment revenue grew 41% YoY in Q4 to INR 650.72 million.
Recorded an exceptional gain of INR 69.96 million in Q4 FY26 from the sale of investment in a subsidiary.
👀 What to Watch
Investors should take note of the significant margin improvement and the strong recovery in the poultry segment. The healthy dividend payout and profit growth make this a positive update for long-term shareholders.
Hester Biosciences Q4 Consolidated PAT Surges 974% YoY; Recommends INR 11 Dividend
Hester Biosciences reported a massive 974% year-on-year surge in consolidated Q4 PAT to INR 165.46 million, driven by a 22% increase in revenue and significant margin expansion. For the full year FY26, consolidated PAT nearly doubled to INR 574.84 million despite a modest 7% revenue growth, reflecting improved operational efficiency and product mix. The Board has recommended a dividend of INR 11 per share (110%), while the Poultry Healthcare division remains the primary growth engine with 41% Q4 growth. However, the Animal Healthcare division continues to face headwinds from delayed government programs, declining 6% in Q4.
Key Highlights
Consolidated Q4 PAT jumped 974% YoY to INR 165.46 million; Standalone Q4 PAT rose 174% to INR 263.84 million.
Board recommended a final dividend of INR 11 per equity share (110%) for the financial year 2025-26.
Poultry Healthcare division revenue grew 41% in Q4 FY26, while Animal Healthcare revenue declined 6% due to government program delays.
Consolidated EBITDA margins improved significantly to 36% in Q4 FY26 from 17% in the previous year's quarter.
Successfully received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine during the quarter.
👀 What to Watch
The sharp recovery in profitability and strong dividend payout make this a positive result for shareholders. Investors should monitor the scale-up of the new BSL 3 facility and the recovery of the Animal Healthcare segment as government tenders resume.
Hester Biosciences Recommends ₹11 Dividend; FY26 PAT Surges 64% to ₹521 Million
Hester Biosciences has recommended a final dividend of ₹11 per share for FY26, representing a 110% payout on face value. The company reported a strong financial performance with annual standalone Profit After Tax (PAT) rising 64% to ₹521 million, driven by significant growth in the Poultry Healthcare segment. Quarterly performance was particularly robust, with Q4 PAT jumping to ₹263.84 million from ₹96.35 million in the previous year. Additionally, the board approved the re-appointment of Ms. Priya Gandhi as Executive Director for a three-year term.
Key Highlights
Recommended a final dividend of ₹11 per equity share (110%) for the financial year 2025-26.
Standalone annual Profit After Tax (PAT) increased by 63.6% YoY to ₹521 million.
Q4 FY26 Revenue from operations grew 22% YoY to ₹937.13 million compared to ₹766.72 million.
Poultry Healthcare segment revenue grew to ₹2,061.31 million in FY26 from ₹1,665.83 million in FY25.
Earnings Per Share (EPS) improved significantly to ₹61.24 for FY26 compared to ₹37.43 in FY25.
👀 What to Watch
Investors should consider the strong bottom-line growth and healthy dividend payout as a sign of improved operational efficiency. The significant jump in Q4 margins and Poultry segment growth makes this a positive development for long-term holders.
Hester Biosciences Q4 Net Profit Jumps 174% to ₹26.38 Cr; Declares ₹11 Dividend
Hester Biosciences reported a robust performance for Q4 FY26, with standalone revenue growing 22% YoY to ₹937.13 million. Net profit for the quarter surged 174% to ₹263.84 million, significantly bolstered by an exceptional gain of ₹69.96 million from the sale of a subsidiary. For the full year FY26, the company achieved a net profit of ₹521.00 million, a 64% increase over FY25. The Board has recommended a healthy dividend of ₹11 per share (110% of face value).
Key Highlights
Q4 FY26 Standalone Revenue rose 22.2% YoY to ₹937.13 million compared to ₹766.72 million.
Standalone Net Profit for Q4 surged to ₹263.84 million from ₹96.35 million in the previous year.
Recommended a final dividend of ₹11 per equity share for the financial year 2025-26.
Poultry Healthcare segment revenue grew 24% in FY26, reaching ₹2,061.31 million.
Full-year FY26 Earnings Per Share (EPS) increased to ₹61.24 from ₹37.43 in FY25.
👀 What to Watch
Investors should view the strong recovery in the poultry segment and the significant jump in annual profitability as positive indicators. The stock remains attractive for long-term investors given the consistent dividend payout and the operationalization of new BSL-3 facilities.
Hester Biosciences Credit Rating Downgraded to CARE BBB; Stable by CARE Ratings
CARE Ratings has downgraded Hester Biosciences' long-term bank facilities from 'CARE BBB+; Stable' to 'CARE BBB; Stable' and short-term ratings from 'A2' to 'A3+'. The downgrade follows a review of the company's FY25 audited and 9MFY26 unaudited financial performance. Management has labeled this downgrade as 'transitional,' pointing towards recent improvements in operating margins, ROCE, and debt coverage ratios post-September 2025. The company maintains adequate liquidity for its debt obligations and has recently secured a manufacturing license for the Avian Influenza H9N2 vaccine.
Key Highlights
Long-term bank facilities downgraded to CARE BBB; Stable from CARE BBB+; Stable
Short-term bank facilities downgraded to CARE A3+ from CARE A2
Total bank facilities rated by CARE Ratings amount to ₹131.47 crore
Management reports improved debt coverage indicators in H1FY26 despite the rating action
Company holds 75% global market share in PPR vaccine and 35% Indian market share in poultry vaccines
👀 What to Watch
Investors should exercise caution due to the credit downgrade, which may increase future borrowing costs. Monitor upcoming quarterly results to see if the management's claim of a 'transitional' phase reflects in actual bottom-line improvement and debt reduction.
Hester Biosciences to Divest 43.81% Stake in Texas Lifesciences for INR 92 Million
Hester Biosciences has announced the divestment of a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for a total consideration of INR 92 million. Following the sale to Ticop Life Private Limited, Hester will retain an 11% stake, and TLPL will cease to be a subsidiary. TLPL reported a turnover of INR 285.89 million in FY 2024-25, though over 97% of its sales were internal to Hester. This move allows Hester to unlock capital while maintaining a strategic business relationship with the entity.
Key Highlights
Divesting 43.81% stake out of 54.81% total holding in Texas Lifesciences Private Limited.
Total aggregate consideration for the sale is INR 92 million.
TLPL's FY 2024-25 turnover was INR 285.89 million with a net worth of INR 134.17 million.
Hester will maintain an 11% equity stake and continue business operations with TLPL.
The transaction is expected to be completed within three months from March 5, 2026.
👀 What to Watch
Investors should watch for the impact on consolidated margins since TLPL's internal sales were previously eliminated, and monitor the utilization of the INR 92 million proceeds.
Hester Biosciences to Divest 43.81% Stake in Texas Lifesciences for INR 92 Million
Hester Biosciences has approved the divestment of a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for a total consideration of INR 92 million. Following the sale to Ticop Life Private Limited, Hester will retain an 11% stake, and TLPL will no longer be a subsidiary. TLPL reported a turnover of INR 285.89 million in FY 2024-25, though over 97% of its sales were internal to Hester. The transaction is expected to be completed within three months and represents a strategic rationalization of the company's subsidiary portfolio.
Key Highlights
Divesting 43.81% stake in Texas Lifesciences for an aggregate value of INR 92 million
Hester will retain an 11% equity stake and continue business relations with TLPL
TLPL FY 2024-25 turnover was INR 285.89 million with a net worth of INR 134.17 million
Over 97% of TLPL's sales were internal to Hester, resulting in elimination during consolidation
The share transfer transaction is expected to be completed within a 3-month period
👀 What to Watch
Investors should note this as a portfolio streamlining move that unlocks INR 92 million in cash without significantly impacting consolidated revenue due to the high volume of internal sales. Monitor for any impact on procurement margins as TLPL moves from a subsidiary to an external supplier.
Hester Biosciences Re-appoints Rajiv Gandhi as CEO & MD for 3 Years with 99.54% Approval
Hester Biosciences has announced the successful re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director for a three-year term effective from April 1, 2026. The special resolution was passed via a postal ballot process with an overwhelming 99.54% of valid votes cast in favor. While the promoter group showed 100% support, a significant majority of the small institutional voting block (99.24%) voted against the resolution. This move ensures leadership continuity for the company through March 2029.
Key Highlights
Special resolution for re-appointment of Rajiv Gandhi as CEO & MD passed with 99.54% majority.
The new term is effective for three years from April 1, 2026, to March 31, 2029.
Total valid votes cast represented 4,075,085 shares, with 4,056,419 votes in favor.
Promoter group cast 3,451,082 votes, showing 100% internal support for the leadership.
Public institutional holders showed 99.24% dissent, though this represented only 18,570 shares.
👀 What to Watch
Investors should take confidence in the leadership continuity which supports long-term strategic stability. No immediate action is required as the current management remains at the helm.
Hester Biosciences Proposes Re-appointment of Rajiv Gandhi as CEO & MD for 3 Years
Hester Biosciences has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director. The proposed tenure is for three years, spanning from April 1, 2026, to March 31, 2029. This move is intended to ensure leadership continuity, and the resolution is being proposed as a Special Resolution. Shareholders can participate in the remote e-voting process from February 8 to March 9, 2026.
Key Highlights
Proposed re-appointment of Mr. Rajiv Gandhi as CEO & Managing Director for a 3-year term.
The new term is scheduled to run from April 1, 2026, through March 31, 2029.
Remote e-voting period is set for February 8, 2026, to March 9, 2026, with results by March 11.
The resolution requires approval as a Special Resolution via postal ballot.
The cut-off date for shareholder eligibility was fixed as January 30, 2026.
👀 What to Watch
This is a routine leadership continuity event for the promoter-led company. Investors should support the resolution to maintain management stability, though no immediate impact on stock price is expected.
